CA2250143A1 - Inhibiteurs de la farnesyle-proteine transferase - Google Patents

Inhibiteurs de la farnesyle-proteine transferase Download PDF

Info

Publication number
CA2250143A1
CA2250143A1 CA002250143A CA2250143A CA2250143A1 CA 2250143 A1 CA2250143 A1 CA 2250143A1 CA 002250143 A CA002250143 A CA 002250143A CA 2250143 A CA2250143 A CA 2250143A CA 2250143 A1 CA2250143 A1 CA 2250143A1
Authority
CA
Canada
Prior art keywords
unsubstituted
compound
substituted
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002250143A
Other languages
English (en)
Inventor
Jeffrey Bergman
Christopher Dinsmore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9610654.7A external-priority patent/GB9610654D0/en
Application filed by Individual filed Critical Individual
Publication of CA2250143A1 publication Critical patent/CA2250143A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés inhibiteurs de la farnésyle-protéine transférase (FTase) et de la farnésylation de la protéine oncogène Ras. L'invention concerne également, non seulement des compositions chimiothérapiques contenant les composés de l'invention, mais aussi des procédés d'inhibition de la farnésyle-protéine transférase et de la farnésylation de la protéine oncogène Ras.
CA002250143A 1996-04-03 1997-03-31 Inhibiteurs de la farnesyle-proteine transferase Abandoned CA2250143A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1466896P 1996-04-03 1996-04-03
US60/014,668 1996-04-03
GB9610654.7 1996-05-21
GBGB9610654.7A GB9610654D0 (en) 1996-05-21 1996-05-21 Inhibitors of farnesyl-protein transferase

Publications (1)

Publication Number Publication Date
CA2250143A1 true CA2250143A1 (fr) 1997-10-09

Family

ID=26309375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002250143A Abandoned CA2250143A1 (fr) 1996-04-03 1997-03-31 Inhibiteurs de la farnesyle-proteine transferase

Country Status (5)

Country Link
EP (1) EP0959883A4 (fr)
JP (1) JP2000507584A (fr)
AU (1) AU715604B2 (fr)
CA (1) CA2250143A1 (fr)
WO (1) WO1997036583A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027752A1 (fr) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
JP2000507589A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
HUP0102473A3 (en) * 1997-12-22 2003-07-28 Schering Corp Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
DE69937440T2 (de) 1998-05-20 2008-08-28 Dai Nippon Printing Co., Ltd. Isolierender behälter
AU760027B2 (en) 1998-07-02 2003-05-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1090011A4 (fr) 1998-07-02 2005-04-06 Merck & Co Inc Inhibiteurs de prenyl-proteine transferase
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497591A (en) * 1968-11-19 1970-02-24 Colgate Palmolive Co Dental preparations containing imidazole derivative
DE2814355C3 (de) * 1978-04-03 1982-01-21 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 4-Methyl-5-[(2-aminoäthyl)-thiomethyl]-imidazol-dihydrochlorid
DE3219113A1 (de) * 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
IL117580A0 (en) * 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997029092A1 (fr) * 1996-02-09 1997-08-14 James Black Foundation Limited Ligands du recepteur de l'histamine h¿3?

Also Published As

Publication number Publication date
EP0959883A4 (fr) 2001-05-09
EP0959883A1 (fr) 1999-12-01
AU715604B2 (en) 2000-02-03
WO1997036583A1 (fr) 1997-10-09
JP2000507584A (ja) 2000-06-20
AU2596897A (en) 1997-10-22

Similar Documents

Publication Publication Date Title
US5780488A (en) Inhibitors of farnesyl-protein transferase
US5710171A (en) Bisphenyl inhibitors of farnesyl-protein transferase
US5914341A (en) Inhibitors of farnesyl-protein transferase
US5925651A (en) Inhibitors of farnesyl-protein transferase
CA2249665A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2216707A1 (fr) Inhibiteurs de farnesyl-proteine transferase
CA2249615A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2250353A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
US5780492A (en) Inhibitors of farnesyl-protein transferase
CA2249559A1 (fr) Inhibiteurs de farnesyle-proteine transferase
CA2249641A1 (fr) Inhibiteurs de farnesyl-proteine transferase
CA2250936A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
EP0880320A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2249604A1 (fr) Inhibiteurs de farnesyl-proteine transferase
AU707416B2 (en) Inhibitors of farnesyl-protein transferase
CA2249645A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2249605A1 (fr) Inhibiteurs de transferase de farnesyl-proteine
CA2250143A1 (fr) Inhibiteurs de la farnesyle-proteine transferase
CA2249599A1 (fr) Inhibiteurs de la farnesyle-proteine transferase
US5922883A (en) Inhibitors of farnesyl-protein transferase
CA2249650A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2250192A1 (fr) Inhibiteurs de farnesyle-proteine transferase
AU706629B2 (en) Inhibitors of farnesyl-protein transferase
US5981562A (en) Inhibitors of farnesyl-protein transferase
EP0877610A1 (fr) Inhibiteurs de farnesyl-proteine transferase

Legal Events

Date Code Title Description
FZDE Dead